Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15330049 | 0.75 | TDP1 (0.34) | NQO1 | |
| SCHEMBL12478198 | 0.75 | GAA (0.43) | NQO1 | |
| SCHEMBL17298246 | 0.75 | NOS3 (0.38) | NQO1 | |
| SCHEMBL296626 | 0.70 | PTK2 (0.50) | NQO1 | |
| Hydrochloric Acid SCHEMBL22686894 | 0.67 | PTK2 (0.47) | NQO1 | |
| Hydrochloric Acid SCHEMBL5861979 | 0.67 | PTK2 (0.47) | NQO1 | |
| Hydrochloric Acid SCHEMBL5051825 | 0.67 | PTK2 (0.47) | NQO1 | |
| SCHEMBL17299130 | 0.66 | NQO1 (0.39) | NQO1 | |
| SCHEMBL29534248 | 0.66 | PTK2 (0.54) | — | |
| SCHEMBL10027390 | 0.66 | PTK2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | LU QING BIN (CA) | 2019-11-05 | — | — | US | disclosed |
| US-9655965-B2 | Radiosensitizer compounds for use in combination with radiation | Lu qing-bin (CA) | 2017-05-23 | — | — | US | disclosed |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu qing-bin (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu qing-bin (CA) | 2016-08-18 | — | — | US | disclosed |
| US-20150343059-A1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | Lu qing-bin (CA) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463662-B2 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | TOP2B, POLR2B, RB1 | NQO1 639/4885 |
| US-20150343059-A1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | RB1, ERCC2, RBBP7 | NQO1 124/4885 |
| US-20160235743-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | TOP2B, POLR2B, RB1 | NQO1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.